By Ahmed Aboulenein and Maggie Fick WASHINGTON (Reuters) -AstraZeneca plans to spend $50 billion to expand manufacturing and ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D) ...

AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

AstraZeneca (AZN) is expanding its US footprint with a $50 billion investment as drugmakers move to avoid steep tariffs on ...

AstraZeneca (AZN, Financials) said Monday it will invest $50 billion in the United States by 2030 to expand manufacturing and ...

With the threat of tariffs looming for medicines imported to the United States, AstraZeneca has unveiled a plan to invest $50 ...

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...

The $50 billion investment in the United States by AstraZeneca is just one of many significant investments expected from pharmaceutical companies as they react to President Donald Trump’s ...

AstraZeneca said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

British pharmaceuticals giant AstraZeneca has revealed it plans to invest $50 billion (£37 billion) in America over the next ...